Stories

Elisabetta Leo is moving science forward at the heart of early development. This involves progressing nonclinical data and novel molecules in oncology, from bench to bedside.

Philippe Lopes-Fernandes, EVP & Chief Business Officer, shares how Ipsen’s tenacious approach to dealmaking is transforming breakthrough science into global impact—solidly.

Developing an antibody-drug conjugate (ADC) is a technical challenge. Across Ipsen’s work in ADCs Will Olughu leads a team driving the chemistry, manufacturing, and controls (CMC) effort to bring this complex science into reality.

It is a pivotal moment in Ipsen’s oncology journey, advancing our clinical-stage pipeline with bold science and a clear purpose – to bring meaningful innovation to the patients who need it most, transforming what patients and healthcare systems can expect from cancer treatment.

The future of biopharma will be shaped not by the biggest players, but by the most agile ones. That is why I believe our operating model at Ipsen gives us a real advantage in today’s fast-moving landscape.